Icon Bioscience has submitted a New Drug Application to the Food and Drug Administration (FDA) for their product, Dexycu (IBI-10090), a novel treatment for inflammation associated with post-operative cataract surgery.  

Dexycu is a long-acting, biodegradable extended-release formulation of the anti-inflammatory agent dexamethasone, which is injected into the anterior chamber of the eye following cataract surgery. The one-time injection is administered with Icon’s Varisome drug-delivery technology. 

Related Articles

Current standard-of-care for inflammation follow cataract surgery involves self-administering medicated eye-drops for a period of weeks. The proposed injection could possibly cut out dosing and adherence issues.

“Dexycu has been designed to improve the management of post-surgery inflammation by offering the physician the option of a single administration of the sustained-released anti-inflammatory agent at the site of action,” said Eric D. Donnenfeld, MD, Clinical Professor of Ophthalmology, NYU, and lead investigator for Dexycu clinical studies. 

Continue Reading

For more information visit Iconbioscience.com.